Background: Laparoscopic common bile duct exploration (LCBDE) has been proven to be a safe, efficient, and cost-effective option for the management of common bile duct (CBD) stones. There are two guiding methods during LCBDE: fluoroscopic or choledochoscopic. Most surgeons prefer the use of flexible choledochoscopy at LCBDE, but it is a fragile, delicate, and expensive instrument. The aim of this work was to report our experience in fluoroscopically guided LCBDE.
Patients And Methods: A retrospective review of all patients who underwent LCBDE in the Mansoura Gastroenterology surgical center between March 2007 and September 2014 was performed. Patients with gallstones and concomitant CBD stones were included. After the initial assessment, all patients fulfilling the criteria of enrollment underwent magnetic resonance cholangiopancreatography, and only patients with magnetic resonance cholangiopancreatography or endoscopic retrograde cholangiopancreatography evidence of CBD stones were included. Choledochoscopy was not used in any patient, and we depended on fluoroscopic guidance for CBD stone retrieval in all LCBDE.
Results: A total of 290 patients were assessed for LCBDE: 76 patients were excluded; 11 patients were not completed laparoscopically due to negative intraoperative cholangiography (n=7) and conversion to laparotomy (n=4); the remaining 203 patients were analyzed. LCBDE failed in 16 of the 203 (7.9%) cases, with a success rate of 92.1%. The median operative time was 79 minutes, and the median hospital stay was 2.4 days. Complications were bile leakage (n=4), mild pancreatitis (n=2), wound infection (n=2), port hernia (n=1), and internal hemorrhage (n=1).
Conclusions: Compared with published studies using choledochoscopy at LCBDE, we found comparable results in terms of the success/failure rate, the morbidity and mortality, the operative time, and the length of hospital stay. LCBDE under fluoroscopic guidance may be as safe and efficient as with choledochoscopic guidance.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SLE.0000000000000198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endoscopic "combined-arms approach" for the management of a giant intraductal papillary mucinous neoplastic lesion of the bile duct.
Endoscopy
December 2025
Department of Gastroenterology, Hopital Nord, Marseille, France.
Endoscopic removal of intrahepatic bile duct stones using a slim basket catheter passed through a device delivery system in a patient who had undergone pancreaticoduodenectomy.
Endoscopy
December 2025
Gastroenterology, Kakogawa Central City Hospital, Kakogawa, Japan.
Endoscopic ultrasound-guided hepaticojejunostomy using forward-viewing echoendoscope for hepatic duct obstruction due to postoperative bile duct injury.
Endoscopy
December 2025
Department of Gastroenterology, Tonan Hospital, Sapporo, Japan.
Innovative Construction and Application of Bile Duct Organoids: Unraveling the Complexity of Bile Duct Diseases and Potential Therapeutic Strategies.
Cancer Lett
March 2025
School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Hepato-Pancreato-Biliary Center, Tsinghua University, Beijing, 102218, China; Clinical Translational Science Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, 102218, China; Key Laboratory of Digital Intelligence Hepatology (Ministry of Education/Beijing), School of Clinical Medicine, Tsinghua University, Beijing, 100084, China. Electronic address:
The biliary system is crucial for liver function, regulating bile production, secretion, and transport. Dysfunctions within this system can lead to various diseases, such as cholangiopathies and biliary fibrosis, which may progress from benign to malignant states like cholangiocarcinoma. While liver organoid research is well-established and technologically advanced, bile duct organoids (BDOs) offer significant potential.
View Article and Find Full Text PDF[A Case of Bullous Pemphigoid after Combined Chemotherapy of Durvalumab, Gemcitabine and Cisplatin for Intrahepatic Cholangiocarcinoma].
Gan To Kagaku Ryoho
February 2025
Dept. of Surgery, Kaizuka City Hospital.
The patient is a 66-year-old man. He underwent a total of 9 courses of GCD therapy(gemcitabine+cisplatin+durvalumab)for intrahepatic cholangiocarcinoma with direct invasion of the greater omentum and abdominal wall and surrounding peritoneal dissemination. The tumor had shrunk and was judged to be curative, and laparoscopic hepatic S4a/S5 subsegmentectomy and S6 partial hepatectomy were performed at 8 months after the initial diagnosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!